Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment.
Ontology highlight
ABSTRACT: The application of cannabis products in oncology receives interest, especially from patients. Despite the plethora of research data available, the added value in curative or palliative cancer care and the possible risks involved are insufficiently proven and therefore a matter of debate. We aim to give a recommendation on the position of cannabis products in clinical oncology by assessing recent literature. Various types of cannabis products, characteristics, quality and pharmacology are discussed. Standardisation is essential for reliable and reproducible quality. The oromucosal/sublingual route of administration is preferred over inhalation and drinking tea. Cannabinoids may inhibit efflux transporters and drug-metabolising enzymes, possibly inducing pharmacokinetic interactions with ant
SUBMITTER: Woerdenbag HJ
PROVIDER: S-EPMC10093248 | biostudies-literature | 2023 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA